Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Releasing Hormone (GHRH) Analog |
| Risk Level | High |
| Administration | Subcutaneous Injection |
| Typical Frequency | Once Daily |
| Estimated Half-Life | Approximately 30 Minutes |
| Primary Research Interest | Visceral Fat Reduction / HGH Axis Support |
This material is provided strictly for educational and informational purposes related to peptide research and endocrine compounds. Tesamorelin is a potent biologically active GHRH analog that may significantly alter growth hormone and IGF-1 signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 20 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 6.67 mg/mL
At this concentration:
• 1 mg = 0.150 mL (15.0 units)
• 2 mg = 0.300 mL (30.0 units)
2. Route of Administration
Tesamorelin is most commonly administered as a subcutaneous injectable GHRH analog.
- Primary Route: SubQ Injection
- Preferred Timing: Before bedtime
- Administration Notes: Bedtime administration is commonly discussed in an attempt to align with natural nocturnal growth hormone pulses
3. Typical Research Protocols
- Product Strength: 6.67 mg/mL
- Typical Delivered Amount: 1–2 mg daily before bedtime
- Frequency: Once per day
- Cycle Length: 16 weeks on / 16 weeks off
- Special Notes: Tesamorelin use is associated with increased IGF-1 signaling, which has raised theoretical concerns surrounding tumor growth and malignancy progression. Use should be approached cautiously in individuals with a history of cancer or malignancy.
4. Summary
Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analog originally developed to stimulate endogenous growth hormone production.
Research and clinical interest in Tesamorelin primarily center around visceral fat reduction, body composition support, and modulation of the HGH / IGF-1 axis.
5. Mechanism of Action
Tesamorelin stimulates the pituitary gland to increase endogenous growth hormone release, which subsequently elevates circulating IGF-1 levels.
Potential downstream effects discussed in research include:
- Increased endogenous HGH secretion
- Elevated IGF-1 signaling
- Visceral fat reduction
- Improved lipolysis signaling
- Enhanced recovery and tissue repair support
Unlike direct HGH administration, Tesamorelin works upstream through pituitary stimulation pathways.
6. Potential Benefits
- Potential reduction in visceral fat
- Improved body composition
- Enhanced recovery support
- Increased endogenous HGH production
- Possible improvements in sleep and recovery quality
- Potential metabolic support
7. Potential Risks / Side Effects
High
- Elevated IGF-1 levels
- Water retention
- Joint pain
- Insulin resistance concerns
- Headaches
- Nausea
- Potential tumor growth signaling concerns
- Endocrine dysregulation concerns
8. Half-Life
Tesamorelin is commonly discussed as having an estimated plasma half-life of approximately 30 minutes.
Despite the relatively short circulating duration, downstream growth hormone and IGF-1 signaling effects may persist substantially longer.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Diabetes or insulin resistance
- Severe endocrine disorders
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Growth hormone and IGF-1 literature
- Peer-reviewed endocrinology journals
CKF Tide Tables 